ClinicalTrials.gg
CompletedNCT04610736Updated Jul 31, 2025

TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide

A Phase 1 interventional study of Temozolomide Oral Suspension in Pediatric Cancer, sponsored by Orphelia Pharma. Completed at 11 sites in 5 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Orphelia Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Study summary

Non-randomized, international, multi-centre, open-label, single arm study to determine the pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year and over.

Read the detailed description

The TEMOkids study is an international open-label, non-randomized, prospective, single-arm phase 1 study to determine the pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year and over.

Patients will be subject to at least one 21 or 28-day treatment cycle involving administration of an oral suspension of temozolomide (KIMOZO) for five consecutive days followed by 16 or 23-days resting period, with determination of the PK parameters on the first treatment day.

Five (5) additional cycles will be allowed under compassionate use regimen. The compassionate use period could be extended at the discretion of the investigator and in agreement with the sponsor. Safety and activity data will be collected during the compassionate follow-up period.

The study will be held in multiple sites spread across Europe.

02

Conditions studied

  • Pediatric Cancer

Keywords

  • neuroblastoma
  • other pediatric cancers requiring temozolomide
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 49 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Orphelia Pharma is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients in need of temozolomide (all indications with 5-day treatment per 21- or 28-day cycle).
  • Male and female patients aged 1 to less than 18 years
  • Patients who have signed the or for which one, both parents or legal guardian (depending on local legislation) have signed the informed consent.
  • Patients having records of coverage by a health insurance
  • ≥ 3 months
  • Adequate haematological function:

    • ≥ 80 g/L (transfusion support authorized)
    • ≥ 1.0 x 10e9 cells/L
    • count ≥ 100 x 10e9 cells/L (without transfusion support)
    • in case of bone marrow involvement: neutrophils ≥ 0.5 x 10e9 cells/L and platelets ≥75 x 10e9 cells/L
  • Adequate renal function:

    • Creatine clearance ≥ 60 mL/min.1.73m² according to the Schwartz formula [1] or its modified form [2]
  • Adequate hepatic function:

    • ≤1.5 x
    • and ALT ≤ 2.5 x ULN (AST, ALT 5xULN in case of liver )
  • Lansky Score ≥ 70%

Exclusion criteria

Exclusion Criteria:

  • Patients who are co-administrated at day one with sodium valproate as it decreases the clearance of temozolomide
  • Patients with (naso)gastric tube administration of temozolomide during first cycle of treatment.
  • Patients already enrolled in studies investigating temozolomide or other new drugs.
  • A post-menarche female with a positive blood/urine pregnancy test at inclusion.
  • Known or to temozolomide or any chemically close substance
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Single arm

    Temozolomide 40 mg/ml, Oral suspension

    Drug: Temozolomide Oral Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Population Phamacokinetic parameter: AUC24

    Estimated by a population analysis performed with NONMEM (7.4)

    Time frame: At Day 1 of treatment cycle 1 (each cycle is 21 or 28 days) with post-dose samples collected at about 0.15, 0.5, 1, 2.5, and 7 hours post dose

  2. Population Phamacokinetic parameter: Cmax

    Estimated by a population analysis performed with NONMEM (7.4)

    Time frame: At Day 1 of treatment cycle 1 (each cycle is 21 or 28 days) with post-dose samples collected at about 0.15, 0.5, 1, 2.5, and 7 hours post dose

  3. Population Phamacokinetic parameter: T1/2

    Estimated by a population analysis performed with NONMEM (7.4)

    Time frame: At Day 1 of treatment cycle 1 (each cycle is 21 or 28 days) with post-dose samples collected at about 0.15, 0.5, 1, 2.5, and 7 hours post dose

Secondary outcomes

  1. Acceptability of the oral suspension of temozolomide: score

    Scoring with a standardized assessment tool: CAST - ClinSearch Acceptability Score Test®. This tool measures 9 observational drivers of drug acceptability.

    Time frame: At Day 1 and Day 5 of treatment cycle 1 (each cycle is 21 or 28 days)

  2. Incidence of treatment-emergent adverse events

    Adverse events collected directly by investigators when patient is hospitalized and through patient diary completed by caregivers and medically controlled by investigators when patient is at home

    Time frame: Through study completion, an average of 6 months including compassionate use period

  3. Activity of the oral suspension of temozolomide

    Activity assessment (complete or partial response, stable disease, disease progression)

    Time frame: At the end of each 21- or 28-day treatment cycle of the compassionate use period

07

Study locations

11 sites
  • Centre Oscar Lambret
    Lille, 59000, France
  • Institut d'Hématologie et d'Oncologie Pédiatrique
    Lyon, 69008, France
  • CHU Timone Enfants
    Marseille, 13005, France
  • Institut Curie
    Paris, 75005, France
  • Gustave Roussy
    Villejuif, 94800, France
  • Charité University Medicine Berlin
    Berlin, 13353, Germany
  • Hopp Children's Cancer Center Heidelberg
    Heidelberg, 69120, Germany
  • Princess Maxima Center for Pediatric Oncology
    Utrecht, 3584 CS, Netherlands
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Great Ormond Street Hospital for Children
    London, WC1N 3JH, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2023, 21 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 21 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2020
First posted
Oct 30, 2020
StartActual
Mar 16, 2021
Primary completionActual
Jan 15, 2023
CompletionActual
Jul 3, 2023
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04610736
Lead sponsor
Orphelia Pharma
Collaborators
ClinSearch
Responsible party
Sponsor
First posted
Oct 30, 2020
Start date
Mar 16, 2021
Primary completion
Jan 15, 2023
Completion
Jul 3, 2023
Last update
Jul 31, 2025

Study contacts

Samuel Abbou, MD
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion